T h e development of enzyme kinetics, protein crystallography and NMR studies allows enzymecatalysed reactions to be described in terms of mechanistic chemistry, albeit applied to relatively enormous molecules. These nanomachines, which so inspired Drexler's Engines of Creation, have been working in biological systems for over three billion years and represent a useful knowledge base for our further understanding of mechanistic biology. They also provide a tantalizing glimpse into what may be the basis for novel technologies with industrial applications for the twenty-first century.
doing this very successfully for 3.5 billion years ! That being said, there is, I feel, real potential in a fusion of the 'off-the-shelf' nanomachines in the protein chemist's armoury and the current development of novel materials by chemists and physicists, and I will return to this topic briefly later.
T h e marriage of kinetic and structural data allows mechanistic interpretations of the working of these nanomachines, and these will be discussed for the slow kinetic transient of arylsulphatase-A and the 'floppy' u2-loop of glutathione S-transferase P1-1 (GSTP1-1). This mobile element may play a role as a redox sensor to monitor oxidative stress, and recent results suggest that this may provide a role in directing damaged cells to commit suicide. Much of this work has been the result of a fruitful collaboration we have had with Miquel Coll's lab in Barcelona on structural studies of one member of the glutathione S-transferase supergene family, G S T P I , and more recently biliverdin-IXP reductase ('BVR-B '), a small enzyme with complicated behaviour.
The slow kinetic transients of arylsulphatase A
T h e initial part of the progress curve for arylsulphatase A with nitrocatechol sulphate as substrate reveals a linear initial rate over the first 4 to 5 min. Indeed, if we plot the initial rates as a function of the substrate concentration we obtain classical hyperbolic kinetics, which allows us to determine the K , and V , , for this reaction, and to sketch a plausible model in terms of Michaelian kinetics. However, if we look at the data for later time points (e.g., see [3]) it is clear that the initial rate (vo) deviates from linearity. In fact, the rate slows down, not to zero, but to a new steady-state rate that we have defined as of. This is not because the substrate is ' running out ', but rather something else is happening. During the 1950s and 1960s a number of explanations were put forward; however, workers at that time were fascinated with the notion of enzymes with more than one substrate-binding site (which was then in vogue) so that some very complex models were put forward (for a review, see e.g. [4]). It seemed to us that some simpler schemes had been abandoned, and we suggested that addition of one enzyme species (a modified form of the enzyme, F) to the Michaelian mechanism involving free enzyme (E) and the ES complex was sufficient to explain the observed behaviour. In other words, the ES complex occasionally rearranged, not productively 0 2001 Biochemical Society 332 to release products, but to form an inactive species we termed F. If the formation of F (the K, step) was the only additional factor the product-time curve would simply decay to a rate of zero and, since that was clearly not the case, we suggested that the modified form F could slowly break down to regenerate the active enzyme E (the K, step).
This mechanism was shown to give a very simple rate equation that predicts the appearance of product with time, and which we could show fitted our data very well [3]. We were able calculate the rate constants for describing the rate of formation of F (K3) and the rate of flux back from F back to E (K,). T h e rat enzyme, which we did our early work on, was clearly described by this model. T h e behaviour of the rat enzyme was slightly different from that reported for the human and ox enzymes, which are reactivated by several anions, including the product sulphate. This results in product-time curves that show an additional phase of reactivation. Our model for the human and ox enzymes was therefore modified to include an additional step, where the modified form F can bind anions and this form ( F SO,'-) reverts to the free enzyme (E) more rapidly than F. By including sulphate anions from the beginning of the experiment, we predicted a family of transients and this behaviour was mimicked very closely by the experimental data set [3].
We also studied the effect of pH on the initial rate kinetics [S] and on the inactivation kinetics [6] of rat liver arylsulphatase A. T h e initial rate studies suggested that the free enzyme has two ionizable groups, one with a p K of 4.4, which needed to be unprotonated, and one with a p K of 5.8, which needed to be protonated to allow substrate binding to occur. For catalysis to occur, the group with a p K of 4.4 was required, while the protonated group ( p K 5 . 8 in the free enzyme) displayed an altered p K (7.5) in the enzymesubstrate complex. After considering all of the other information available at that time, we suggested a mechanism [5] involving protonation of the bridging oxygen, formation of sulphur trioxide and the alcohol product, and subsequent hydration of the sulphur trioxide (catalysed by the base activation of a water molecule). An advantage of this scheme is that the sulphur trioxide is formed adjacent to the newly formed base, which could be occasionally mis-sulphated, giving a plausible mechanism for the slow kinetic transient. How wrong we were ! It should be remembered that our model at this stage was an unstructured 'blob' with some hypothetical residues in various protonation states. Recently, the crystal structure for human arylsulphatase-A was solved [7] , and this revealed a number of surprising features. At the active site a cysteine residue appears oxidized to form an oxoalanine residue (termed formylglycine by others), and this appears to function as the hydrated gem diol. Additionally a cation (ascribed variously as calcium for the sulphatase-B [8] and magnesium for arylsulphatase-A [7] ) is bound close to the active site. Nature seems to deem this post-translational modification as important, since in some prokaryotes the post-translationally modified residue is a serine, which is also modified to oxoalanine [9] . Using recombinant techniques, the post-translationally modified cysteine of human arylsulphatase-A has been mutated to serine, and this form becomes sulphated, but is then unable to hydrolyse the protein-bound sulphate ester [lo] . This has led to a mechanism involving initial attack by one of the gem diol hydroxyls to produce a sulphated enzyme intermediate (in a socalled ' crypto-Ping Pong ' mechanism) with the other gem diol hydroxyl required for hydrolysis of the enzyme-bound sulphate ester under acidic conditions.
T h e mechanism proposed by Lukatela et al. [7] does not attempt to explain the slow kinetic transient, and further work is required to address this issue. We are currently examining the hypothesis that a rotomer of the sulphated intermediate may be the modified form F (D. Lloyd and T. J. Mantle, unpublished work).
The floppy a2-loop of GSTP I G S T P l (from the Pi family of GSTs) is a member of the G S T supergene family, several members of which, including G S T P l , appear to contribute to cancer chemoprotection and drug resistance, including acquired resistance to chemotherapy (see [ l l ] for an excellent review). There is no doubt that the multiple forms expressed in mammals provide a 'blanket protection' against a large number of potentially toxic electrophilic compounds (whether these are inherently toxic or metabolized to reactive intermediates by the cytochrome P450 system).
Whereas the Alpha and Mu families have diverged considerably, the Pi family appears constrained in evolution, although the mouse clearly expresses two tandem genes [ 121. Muramatsu and co-workers [13, 14] have studied the promoter and 5'-upstream structure of this gene, and have identified an enhancer ( G P E l ) and a silencer (GPS), which appear to be responsible for the major modulations of expression of this gene in the rat. T h e enhancer G P E l is a palindromic TPA-response element (' TRE'), which appears to bind activator protein-1 ('AP-1') and/or additional factors [15] , while the silencer is responsive to the CCAAT-enhancer-binding protein-a (C/EBPa): C/EBPB ratio [14] . Transgenic rats containing a GPEl-chloramphenicol acetyltransferase (' C A T ') construct overexpress C A T in pre-neoplastic nodules, showing that the effect is trans-acting [16] . G S T P l levels are also low in human adult hepatocytes, and have been reported to be increased in a number of tumours, including colon, stomach, oesophagus and lung; however, not in hepatocellular carcinoma. Increased levels of G S T P l in plasma have been reported in certain tumours, notably stomach ; however, great care has to be taken to block G S T P l release from platelets [17] . G S T polymorphisms in the human population have, until recently, focused on the GSTM1 and G S T T l genes for which null alleles appear to predispose to certain types of cancer (see [ 181 for a recent review). Recently, several groups have presented evidence that certain allelic variants of GSTPl seen in the human population are associated with oesophageal [ 19,201 and bladder, testicular and prostate tumours (reviewed in [21] ). This may reflect an inability of these allelic variants to catalyse the efficient conjugation and detoxification of certain carcinogens. It is clear that substitution at residue 105 in human G S T P l has marked effects on thermal stability and kinetic properties with a range of substrates [22] , including polycyclic hydrocarbon derivatives, which have been implicated as ultimate carcinogens.
Intriguingly, the mouse gene is up-regulated by testosterone (probably as a result of a male pattern of growth-hormone expression) so that male mice have been a rich source of the protein for mechanistic and structural studies [23-271. It is noteworthy that male mice are notoriously susceptible to hepatocarcinogenesis when compared with females [28, 29] . Tsuchida and Sato [30] have suggested that G S T P l may play a role as a redox sensor, since this enzyme has a thiol group (Cys-47) that is modified by oxidation and alkylation when G S H or S-alkyl derivatives of glutathione are absent, but which is protected from modification when these ligands are bound to the enzyme. We have developed this concept, and have shown that the protection kinetics using S-hexyl-or S-methyl-glutathione with ethacrynic acid as the modifier are consistent with a mechanism whereby the glutathione adduct locks the enzyme into a conformation where the thiol of Cys-47 is cryptic, and that ethacrynic binding is required to stabilize a conformation where a second molecule of ethacrynic acid can modify . Intriguingly, we have evidence that when the modification/inactivation reagent is H202 (a smaller reagent), the protection kinetics conform to a simple model where the thiol is available in the free enzyme (S. Walsh and T . J. Mantle, unpublished work). It is clear that modification of Cys-47 by iodoacetic acid destabilizes a helical domain (termed the a2-loop), which provides most of the side chains that make contact with glutathione [26] . The modified enzyme is not inactive, as we had originally believed, but simply has the KmGSH increased by three orders of magnitude with very little effect on K,,, [26] . Although GSSG does not apparently form a mixed disulphide with G S T P l , cystine does, suggesting that G S T P l may act as a redox sensor, forming a mixed disulphide with cystine under conditions when G S H is oxidized. T h e quaternary structure of S-cysteine-linked G S T P l has not been determined from any source.
In addition to the species differences in transcriptional regulation of G S T P l (described above), there are also intriguing differences in the reactivity of Cys-47 (Cys-45 in the pig and human). Lo Bello et al. (1995) reported that the pK, of Cys-47 in human G S T P l was 4.2, and that this was stabilized by the formation of a saltbridge between . We had shown previously that the pH-dependence of the interaction of mouse G S T P l with ethacrynic acid indicated a pK, for Cys-47 of 7.6 [24] . Silicon mutagenesis suggests that the pKa of Cys-47 is modulated by the nature of the residue at residue 56 (S. Walsh, G . Grant a n d T . J. Mantle, unpublished work). For the mouse, this is an acidic glutamic acid residue, which 'pulls' Lys-54 away from Cys-47; however, in the human this residue is a neutral glutamine, and this permits a closer electrostatic interaction of Cys-47 with Lys-54. There exist natural mutants at residue 56 (the pig has glutamine; the rat has glutamic acid), and we have examined the pH-dependence of the reaction of these two forms of the enzyme with ethacrynic acid. These results clearly show that there is a difference in the pK, for Cys-47 that depends on the nature of the residue at position 56 [32] ; however, this is only one p H unit [shifting from 7.6 (rat) to 6.6 (pig)]. Similar results have been obtained comparing the native and Glu-56 + Gln mutant of the mouse enzyme (S. Walsh and T . J. Mantle, unpublished work), suggesting that, although the nature of the residue at position 56 affects the pK, of Cys-47, it cannot fully explain a pK, of 4.2 for the human enzyme. Whereas the Cys-47-alkylated mouse enzyme exhibits a large shift in KmcsH from l 0 0 p M to 80 mM, the increase in KmGsH for the pig enzyme is more modest. This would be consistent with less mobility in the a2-loop for the modified pig enzyme compared with the mouse enzyme, and further work is urgently needed to define the behaviour of the human enzyme in this regard. T h e concept that the mobility of the a2-loop may be increased on dissociation of G S H (physiologically, this could result from oxidative stress or alkylation, coupled with multidrug-resistance-related protein/GS-X pump-mediated export), and that this may be augmented by modification of Cys-47 (either by oxidation or alkylation) would be consistent with GSTPl acting as a redox sensor, possibly coupled with some switch function.
An intriguing report has very recently suggested that G S T P l as the monomer may be responsible for modulating the basal activity of c-Jun N-terminal kinase (JNK) by forming a complex with low activity, and that UV/H,02 can promote dissociation of the G S T P l to give elevated J N K activity [33] . We are currently examining the hypothesis that the flexibility of the a2-loop may provide the structural basis for a mechanism to facilitate dissociation of J N K from G S T P l . In support of this hypothesis, which would require lowering G S H to increase the flexibility of the a2-loop, Oguro et al. (1998) have reported that low concentrations of G S H stimulate J N K activity [34] in the up-regulation of haem oxygenase-1 , and treatment of HT29 human colon cells with benzylisothiocyanate, another agent with potential for lowering GSH, causes an increase in J N K activity after 6 h [35] . Of particular note, as many cancer cells overexpress G S T P l , is that this may provide a mechanism to escape apoptosis, which has been implicated as one of the end-points of J N K activity [36] . A similar mechanism may also explain the susceptibility of male mice to hepatocarcinogensis described above.
The future
I hope that this review has demonstrated the utility of the marriage of kinetics and structural biology. These developments have major impli-cations for healthcare and industry. Structural biology looks set to provide exciting new perspectives on pathology. T h e advent of the light and electron microscope heralded a major technical advance in the study of pathology. T h e ability to examine pathological states at the histological level has greatly increased our understanding of many disease states by allowing us to 'look' at the cell and has provided fresh insights to possible therapies. In the last forty years we have witnessed a similar breakthrough in our ability to 'see' details of molecular structure using X-ray crystallography and NMR techniques. T h e benefits are still undergoing evaluation ; however, it seems clear that the ability to 'see' the structure of aberrant mutant or modified proteins has considerably advanced our understanding of pathology, and has additionally provided impetus to the study of pharmacological targets.
Finally, I wish to return now to the paradigm shift of enzymes as nanomachines and the vast potential in a fusion of these 'off-the-shelf' modules of the enzymologist/protein chemist with the current development of novel materials by chemists and physicists. T h e possibility of screening for linking peptides to form a bridge between protein nanomachines and novel materials has been highlighted by Whaley et al.
[37] who have demonstrated that combinatorial phage-display libraries can be used to isolate peptides that bind to a range of semiconductor surfaces (e.g. GaAs). One aspect of our own work, which we are conducting with Werner Blau of our Physics Department and Sylvia Draper of Chemistry, is a programme to link carbon nanotubes with various protein modules to direct electron flow through these physically interesting spaces via protein modules that are already known to handle the efficient transfer of electrons.
My lab has been funded by the Health Research Board, TCD Provost's Appeal Fund, BioResearch Ireland and the Wellcorne Trust.
